MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...
SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SABS) (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces ...
SAB Events & Governance Now Media Ltd. ( (IN:SABEVENTS)) has issued an update. SAB Events & Governance Now Media Limited has initiated a Pre-Packaged Insolvency Resolution Process (PPIRP) under ...
Detailed price information for Sab Biotherapeutics Inc (SABS-Q) from The Globe and Mail including charting and trades.
MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (SABS) (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 ...
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results